How Scientists Selected Survodutide as the Best Dual-Action Obesity Drug From 19 Candidates | Research

The takeaway

Survodutide was chosen from 19 dual glucagon/GLP-1 receptor agonists based on its balanced pharmacology — robust weight loss exceeding pure GLP-1 agonists while maintaining comparable blood sugar control.

25% body weight loss
in obese mice — exceeding what pure GLP-1 agonism achieves

What the researchers found

Survodutide achieved 25% body weight reduction in DIO mice (exceeding semaglutide's GLP-1-only approach) while maintaining comparable antidiabetic efficacy, earning selection from 19 candidates for Phase 3 trials.

Why it matters

Dual-receptor agonists represent the next frontier in obesity treatment, potentially exceeding the already impressive results of GLP-1-only drugs like semaglutide. Understanding how survodutide was selected reveals the rational drug design process behind these breakthroughs.

The numbers in context

19 dual agonists screened. 3 selected for in-depth profiling. Survodutide (BI 456906) chosen as clinical candidate.

How the study worked

Systematic biomarker-driven screening of 19 dual GCGR/GLP-1R agonists using in vitro cAMP assays, in vivo target engagement biomarkers (FGF21, NNMT), oral glucose tolerance, and efficacy studies in DIO and db/db mice.

Who was studied

Preclinical dual GCGR/GLP-1R agonist candidates

What this study cannot tell us

Preclinical data in mice — human pharmacology may differ; DIO mice don't perfectly model human obesity; acute biomarker engagement may not predict chronic efficacy; Phase 3 trial results not yet available; comparison to semaglutide was at single time points.

How to read the evidence

Preliminary preclinical evidence from a rigorous drug development program. Phase 3 human trials ongoing but results not yet available.

When this study was published

Published in 2024, describing the preclinical rationale behind a drug currently in Phase 3 trials.

The bigger picture

The obesity treatment landscape is rapidly evolving from single-target GLP-1 agonists to multi-receptor approaches. Survodutide's dual glucagon/GLP-1 mechanism could deliver greater weight loss by harnessing glucagon's fat-burning effects alongside GLP-1's appetite suppression.

Questions still open

Will survodutide's superior preclinical weight loss translate to greater efficacy than semaglutide in humans?
What is the optimal glucagon:GLP-1 receptor engagement ratio for maximizing weight loss while maintaining glycemic control?
How will survodutide's safety profile compare to pure GLP-1 agonists in large human trials?

Common questions

How is survodutide different from semaglutide?

Semaglutide only activates the GLP-1 receptor. Survodutide activates both glucagon and GLP-1 receptors. The glucagon component adds fat-burning and energy expenditure effects that may produce greater weight loss than GLP-1 alone — in mice it achieved 25% weight reduction.

When will survodutide be available?

It's currently in Phase 3 clinical trials for obesity. These large human studies will determine its safety, efficacy, and optimal dosing before it can be approved for clinical use.

Read the original research

The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.

Diabetes, obesity & metabolism, 26(6), 2368-2378

View on PubMed ↗Publisher’s paper ↗

Citation

Thomas, Leo; Martel, Eric; Rist, Wolfgang; Uphues, Ingo; Hamprecht, Dieter; Neubauer, Heike; Augustin, Robert. (2024). The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.. Diabetes, obesity & metabolism, 26(6), 2368-2378. https://doi.org/10.1111/dom.15551